Deep-Learning-Based de novo Discovery and Design of Therapeutics that Reverse Disease-Associated Transcriptional Phenotypes.

Authors

Jing Xing
Mingdian Tan
Dmitry Leshchiner
Mengying Sun
Mohamed Abdelgied
Li Huang
Shreya Paithankar
Tara Jager, Corewell Health West
Cameron Lawson, Corewell Health West
Reda Girgis, Corewell Health West

Document Type

Article

Publication Date

3-17-2026

Publication Title

Cell

Abstract

Identifying drugs that reverse disease-associated transcriptomic features has been widely explored for drug repurposing, but its potential for de novo drug discovery remains underexplored. Here, we present gene expression profile predictor on chemical structures (GPS), a deep-learning-based drug discovery platform, guided by transcriptomic features, that screens large compound libraries and optimizes lead molecules. We first develop a model that captures transcriptomic perturbation signatures solely from chemical structures and deploy it to library compounds. We refine scoring methods and employ a tree-search method for optimization. By incorporating structure-gene-activity relationships, we uncover drug mechanisms from transcriptomic data. We evaluate GPS across multiple diseases and conduct extensive validation in two cases. In hepatocellular carcinoma, we discover two unique compound series with favorable cellular selectivity and in vivo efficacy. In idiopathic pulmonary fibrosis, we identify one repurposing candidate and one novel anti-fibrotic compound by reversing gene expression of multiple distinct cell types derived from single-cell transcriptomics.

Recommended Citation

Xing J, Tan M, Leshchiner D, Sun M, Abdelgied M, Huang L, et al [Jager T, Lawson C, Girgis R]. Deep-learning-based de novo discovery and design of therapeutics that reverse disease-associated transcriptional phenotypes. Cell. 2026. doi: 10.1016/j.cell.2026.02.016. PMID: 41850287.

Comments

Richard DeVos Heart and Lung Transplant Program

DOI

10.1016/j.cell.2026.02.016

ISSN

1097-4172

PubMed ID

41850287